Saad Usmani, M.D., MBA, FACP Discusses Treatments in Multiple Myeloma Patients
By Rob Dillard - Last Updated: March 31, 2023DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma.
Advertisement
Post Tags:Multiple Myeloma
Advertisement
Related Posts
Patient-derived cells have the potential to enhance drug screening tools and improve patient outcomes.
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.